These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24987370)

  • 1. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
    Godman B; Wettermark B; van Woerkom M; Fraeyman J; Alvarez-Madrazo S; Berg C; Bishop I; Bucsics A; Campbell S; Finlayson AE; Fürst J; Garuoliene K; Herholz H; Kalaba M; Laius O; Piessnegger J; Sermet C; Schwabe U; Vlahović-Palčevski VV; Markovic-Pekovic V; Vončina L; Malinowska K; Zara C; Gustafsson LL
    Front Pharmacol; 2014; 5():106. PubMed ID: 24987370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
    Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
    Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future.
    Vončina L; Strizrep T; Godman B; Bennie M; Bishop I; Campbell S; Vlahović-Palčevski V; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):469-79. PubMed ID: 21831028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
    McGinn D; Godman B; Lonsdale J; Way R; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):73-85. PubMed ID: 20121565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
    Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
    J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.
    Moon JC; Godman B; Petzold M; Alvarez-Madrazo S; Bennett K; Bishop I; Bucsics A; Hesse U; Martin A; Simoens S; Zara C; Malmström RE
    Front Pharmacol; 2014; 5():219. PubMed ID: 25339902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.
    Godman B; Bucsics A; Burkhardt T; Schmitzer M; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):199-207. PubMed ID: 20384566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.
    Bucsics A; Godman B; Burkhardt T; Schmitzer M; Malmström RE
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):809-19. PubMed ID: 23252361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policies to enhance prescribing efficiency in europe: findings and future implications.
    Godman B; Shrank W; Andersen M; Berg C; Bishop I; Burkhardt T; Garuoliene K; Herholz H; Joppi R; Kalaba M; Laius O; Lonsdale J; Malmström RE; Martikainen JE; Samaluk V; Sermet C; Schwabe U; Teixeira I; Tilson L; Tulunay FC; Vlahović-Palčevski V; Wendykowska K; Wettermark B; Zara C; Gustafsson LL
    Front Pharmacol; 2010; 1():141. PubMed ID: 21833180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.
    Godman B; Bucsics A; Burkhardt T; Piessnegger J; Schmitzer M; Barbui C; Raschi E; Bennie M; Gustafsson LL
    Front Pharmacol; 2012; 3():198. PubMed ID: 23308071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
    Fraeyman J; Van Hal G; Godman B; Beutels P
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):141-51. PubMed ID: 23402454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the utilization of venlafaxine after the introduction of generics in Sweden.
    Godman B; Persson M; Miranda J; Skiöld P; Wettermark B; Barbui C; Gustafsson LL
    Appl Health Econ Health Policy; 2013 Aug; 11(4):383-93. PubMed ID: 23754677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.
    Godman B; Bishop I; Finlayson AE; Campbell S; Kwon HY; Bennie M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):469-82. PubMed ID: 23977975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?
    Bennie M; Bishop I; Godman B; Campbell S; Miranda J; Finlayson AE; Gustafsson LL
    Qual Prim Care; 2013; 21(1):7-15. PubMed ID: 23735629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
    Hesse U; Godman B; Petzold M; Martin A; Malmström RE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
    Bennie M; Bishop I; Godman B; Barbui C; Raschi E; Campbell S; Miranda J; Gustafsson LL
    Int J Clin Pract; 2013 Feb; 67(2):170-80. PubMed ID: 23305478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
    Godman B; Shrank W; Wettermark B; Andersen M; Bishop I; Burkhardt T; Garuolienè K; Kalaba M; Laius O; Joppi R; Sermet C; Schwabe U; Teixeira I; Tulunay FC; Wendykowska K; Zara C; Gustafsson LL
    Pharmaceuticals (Basel); 2010 Aug; 3(8):2470-2494. PubMed ID: 27713363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
    Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
    Godman B; Petzold M; Bennett K; Bennie M; Bucsics A; Finlayson AE; Martin A; Persson M; Piessnegger J; Raschi E; Simoens S; Zara C; Barbui C
    BMC Med; 2014 Jun; 12():98. PubMed ID: 24927744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
    Bennie M; Godman B; Bishop I; Campbell S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.